logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Alnylam’s RNAi Product Patisiran Has More Positive News

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them to sell. We see no real reasons for the stock market to be acting as a Bear when the criteria of bullishness are obvious...

Read More

April 25, 2018

0

Sangamo's stock price Soars 52% in pre-market hours on hemophilia A trial results

Sangamo's Stock Price Soars Sangamo Therapeutics' ( SGMO ) stock soared more than 52% in pre-market trading following the announcement with Pfizer ( PFE ), of interim data from Phase 1/2 Alta study evaluating the firm’s gene therapy product SB-525...

Read More

April 2, 2019

0

ImmunoGen Stock Flied on Ovarian Cancer Drug News

The Independent Data Monitoring Committee (IDMC) decided that  ImmunoGen (IMGN)  Phase 3 registration trial evaluating  mirvetuximab soravtansine  as a single-agent therapy for  platinum-resistant ovarian cancer  will continue as planned without modification. ImmunoGen has completed full enrollment of the trial two...

Read More

April 27, 2018

0

The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

The U.S. Food and Drug Administration (FDA) has approved  Portola’s (PTLA)  drug Andexxa ® , the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Commenting on...

Read More

May 4, 2018

0

A Gratifying Exelixis Quarterly Results

It is obvious that  Exelixis’ (EXEL)  first quarter results  do not justify the selling of EXEL  during the whole quarter, but rather condemn it. It is an undeniable fact that Exelixis is doing a great job squeezing the best out...

Read More

May 3, 2018

0

More News for Nektar Therapeutics

Nektar Therapeutics Announces Two Studies of NKTR-358 Nektar Therapeutics ( NKTR ) announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory ( Treg ) cell stimulator, one for psoriasis and one for atopic dermatitis. NKTR-358...

Read More

October 8, 2019

0

Regeneron and Alnylam collaborative agreement will benefit these firms so why the selloff of both?

Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led for 30 years, by physician-scientists   Regeneron Pharmaceuticals ( REGN ) demonstrates an exceptional ability to translate science into medicine. Working diligently Regeneron succeeded...

Read More

April 9, 2019

0

Novartis: Plenty of Good News. See Also: Topics We Will Address in an Upcoming Week in Review

Stock Market Volatility  Stocks can move up and down for various reasons but not all of them have anything to do with the real value of the firms. As a matter of fact, almost all stocks outperform for a while,...

Read More

October 11, 2019

0

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences ( GILD )   and insitro  entered into a strategic collaboration to discover and develop treatments for nonalcoholic steatohepatitis (NASH) . NASH A chronic...

Read More

April 16, 2019

0

Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in Treating Friedreich’s Ataxia

Reata Pharmaceuticals Omaveloxolone for Friedreich's Ataxia On October 14, 2019  Reata Pharmaceuticals ( RETA ) announced the Part 2 portion of its Phase 2 MOXIe trial, with its product omaveloxolone, met its primary endpoint in modifying Friedreich’s ataxia ( FA...

Read More

October 16, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 66
  • 67
  • 68
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy